The 2nd Interstitial Lung Disease (ILD) Summit concluded in Dubai following discussions on the latest scientific guidelines to improve the clinical outcomes for patients living with rare respiratory conditions.
Organized by Boehringer Ingelheim, the event gathered pulmonologists, rheumatologists, and radiologists from the Middle East and Africa region to discuss treatment and management of rare respiratory conditions such as Idiopathic Pulmonary Fibrosis (‘IPF’), Progressive Fibrosing Interstitial Lung Disease (‘PF-ILD’), and Systemic Sclerosis-associated Interstitial Lung Disease (‘SSc-ILD’).
During the summit, attendees were presented with the latest scientific data and insights on effectively detecting and managing ILDs, with expert speakers highlighting the need for a multidisciplinary approach to treat such rare diseases effectively. Workshops on topics such as High-Resolution Computed Tomography (‘HRCT’) readings were also conducted to help address challenges in the diagnosis of pulmonary fibrosis in ILDs, such as Idiopathic Pulmonary Fibrosis (‘IPF’), Progressive Fibrosing (‘PF’), and Systemic Sclerosis (‘Ssc-ILD’).
Mohammed Al-Tawil, Regional Managing Director and Head of Human Pharma at Boehringer Ingelheim for India, the Middle East, Turkey, and Africa (‘IMETA’) region, said, “Pulmonary fibrosis is a major challenge for people suffering from ILDs that can lead to irreversible harm to the lungs, resulting in reduced quality of life. Our ILD Summit drives the peer-to-peer exchange of the latest scientific information that is valuable to shape the therapeutic landscape in clinical practice. Through this forum, we gathered actionable insights from healthcare experts across multiple disciplines to identify the best treatment approach that can significantly improve the lives of patients living with such rare conditions.”
Source: Emirates News Agency